AVANIR Invites Investors to Webcast of Needham & Company Biotechnology Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--May 24, 2005--AVANIR Pharmaceuticals (AMEX:AVN) today announced that its presentation at the fourth annual Needham Biotechnology Conference will be webcast live through the Company's web site at http://www.avanir.com. Vice President and Chief Financial Officer Gregory P. Hanson will be presenting at 11:00 am Eastern time on May 26th from the conference in New York.
The live webcast will be accessible through AVANIR's corporate website via a link on the lower left side of the homepage. To access the webcast, please log on to AVANIR's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software. An archived version of the presentation will be available for 90 days following the conference.
AVANIR Pharmaceuticals is a drug discovery and development company focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious disease. AVANIR's lead product candidate Neurodex(TM), is the subject of a rolling new drug application which is expected to be completed in mid-year 2005. An early stage program targeting inflammatory disease is partnered with Novartis. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.
The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company. The Company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: AVANIR Pharmaceuticals Patrice Saxon, 858-622-5202 email@example.com SOURCE: AVANIR Pharmaceuticals